Skip to main content
TipRanks
Go Ultimate75% OFF

Novonesis (NVZMY) AI Stock Analysis

78 Followers
NVZMY

Novonesis

(Other OTC:NVZMY)

Select Model
Rating:63Neutral
Price Target:$73.00â–²(10.32% Upside)
Action:reiterated
Date:11/07/26

The score is driven primarily by solid underlying operating profitability and positive cash generation, tempered by a recent TTM net loss and volatility in key financial metrics. Technicals are mildly supportive but not strongly bullish. Valuation is a headwind due to a high P/E, while the latest earnings call adds support via reaffirmed growth/margin guidance despite noted free-cash-flow pressure and a delayed recovery in U.S. dietary supplements.

Positive Factors
Diversified Market PositionBalanced exposure across geographies and multiple end markets reduces dependence on any single customer cycle or sector. This diversification can make revenue more resilient through uneven demand, while Novonesis can redirect innovation and commercial focus toward stronger structural growth areas.
Negative Factors
Recent Net Loss and Earnings QualityThe divergence between healthy operating margins and a recent net loss signals pressure below the operating line and reduces confidence in earnings consistency. If this persists, it could weaken retained capital, constrain shareholder returns and make reported profitability less dependable over coming quarters.

Novonesis (NVZMY) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%25%NVZMY+8.19%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$30.88B
Dividend Yield
0.24%
Average Volume (3M)
26.39K
Price to Earnings (P/E)
40.2
Beta (1Y)
0.05
Revenue Growth
10.90%
EPS Growth
30.98%
Country
US
Employees
11,641
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Novonesis Business Overview & Revenue Model

Company Description

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends international...

How the Company Makes Money

Novonesis makes money primarily by selling bio-based ingredients and solutions—most notably enzymes and microbial cultures/biocultures—to business customers (B2B) worldwide. Revenue is generated through commercial supply agreements where customers pu...

Novonesis Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-4.13%|Next Earnings Date:Nov 07, 2024
Earnings Call SentimentPositive

The call was predominantly positive. Novonesis reported solid 7% organic growth, strong margins, broad-based Food & Beverages and Energy momentum, continued innovation, completed strategic investments and confirmed its full-year outlook. The main challenges were the North American dietary supplements downturn, declines in Plant and Tech, elevated CapEx and lower free cash flow, but management expressed confidence in recovery initiatives and the long-term growth trajectory.

Positive Updates

Strong Group Organic Growth and Margin
Novonesis delivered 7% organic sales growth in the first 9 months of 2026, including a good 1 percentage point contribution from sales synergies and close to 2 percentage points from pricing. The adjusted EBITDA margin was 37.9%, up 60 basis points year over year.

Negative Updates

Human Health Weakness in North American Dietary Supplements
Human Health was flat organically in the first 9 months and declined 8% in the third quarter. North American offline dietary supplements declined further, with close to a double-digit decline in the segment. Management attributed the weakness to changing U.S. consumer behavior, reduced buying power, softer probiotic demand in traditional formats and channels, and customer destocking.

Company Guidance

Novonesis confirmed full-year 2026 organic sales growth guidance of 7% to 8%, with fourth quarter organic sales growth expected to be in the range of high-single digit and growth mainly volume-driven, supported by a good 1 percentage point contribution from synergies and around 1.5 percentage point from pricing, while exiting certain countries is expected to have a close to 1 percentage point negative effect; adjusted EBITDA margin is expected to be at the higher end of the 37% to 38% range, Food & Health Biosolutions is expected to deliver organic sales growth around the higher end of the group range, Planetary Health Biosolutions around the lower end of the group range, Human Health to slightly decline, Advanced Health & Nutrition to contribute positively led by HMO and supported by Advanced Protein Solutions, and U.S. Dietary Supplements to recover in the second half of 2027; Agricultural, Energy and Tech growth is expected to be broad-based, led by energy and agricultural, CapEx is expected to be towards the higher end of the 12% to 14% of sales, net debt-to-EBITDA ratio is expected to be around 1.8x at year-end, and a noncash revaluation gain on step acquisition of around EUR 35 million is expected in the fourth quarter.

Novonesis Financial Statement Overview

Summary

Operating profitability and cash generation are solid (TTM gross margin ~55%, EBITDA margin ~30%, positive operating cash flow ~1.24B and free cash flow ~0.70B). The main offsets are weaker earnings quality (TTM net loss despite healthy operating margins) and volatility in revenue, leverage history, and free cash flow.

Income Statement

62Positive

Balance Sheet

58Neutral

Cash Flow

67Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.39B4.16B513.65M17.90B17.55B14.95B
Gross Profit2.47B2.24B242.45M9.72B9.58B8.62B
EBITDA1.49B1.39B1.21B5.47B6.12B5.39B
Net Income-203.32M583.60M40.97M3.02B3.68B3.15B
Balance Sheet
Total Assets16.83B16.35B15.20B28.39B27.98B24.77B
Cash, Cash Equivalents and Short-Term Investments465.50M295.60M284.00M1.16B1.11B1.04B
Total Debt3.18B22.45B1.80B7.73B6.95B482.00M
Total Liabilities5.61B5.49B4.02B14.04B13.76B12.56B
Stockholders Equity11.22B10.86B11.18B13.98B13.84B11.83B
Cash Flow
Free Cash Flow699.76M750.70M660.10M2.10B1.12B2.82B
Operating Cash Flow1.24B1.22B1.02B4.15B4.01B4.06B
Investing Cash Flow-623.97M-1.97B-199.70M-2.13B-2.67B-2.75B
Financing Cash Flow-442.22M753.30M-703.20M-1.89B-1.25B-1.59B

Novonesis Technical Analysis

Technical Analysis SentimentNeutral
Last Price66.17

Price Trends

50DMA67.09Negative
100DMA66.44Positive
200DMA62.60Positive

Market Momentum

MACD-0.24Positive
RSI44.56Neutral
STOCH17.48Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVZMY, the sentiment is Neutral. The current price of 66.17 is below the 20-day moving average (MA) of 68.89, below the 50-day MA of 67.09, and above the 200-day MA of 62.60, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 17.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVZMY.

Novonesis Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

NVZMY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
EMNEMN65Neutral$7.13B11.0010.63%5.39%0.40%-6.58%
SHWSHW65Neutral$83.73B31.5763.49%0.92%7.03%5.95%
NVZMYNVZMY63Neutral$30.89B40.236.17%0.24%10.90%30.98%
ESIESI62Neutral$7.90B38.537.39%0.98%39.62%-14.83%
PPGPPG62Neutral$27.12B17.4419.05%2.36%6.39%27.29%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
SCLSCL55Neutral$1.50B347.630.36%2.39%10.02%-90.50%

* Basic Materials Sector Average

Performance Comparison

0%50%100%NVZMYEMNPPGSHWSCLESIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NVZMY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NVZMYNovonesis A/S - Adr66.175.889.75%
EMNEastman Chemical Company62.368.6716.16%
PPGPpg Industries, Inc.122.7829.8732.15%
SHWSherwin-Williams346.6021.666.66%
SCLStepan Company66.0524.6859.64%
ESIElement Solutions32.579.8043.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026